Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.58 |
| ▸ | NNMT | P40261 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.45 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.37 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.37 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25193229 | 0.98 | MAP4K4 (0.57) | MAP4K4NNMTSMN1; SMN2MKNK1MKNK2 | |
| Methyl Alcohol SCHEMBL20590058 | 0.95 | MAP4K4 (0.55) | MAP4K4NNMTSMN1; SMN2MKNK1MKNK2 | |
| SCHEMBL25513002 | 0.85 | CYP3A4 (0.53) | MAP4K4HTR2AHTR2CHTR2BPDE4A | |
| Hydrochloric Acid SCHEMBL25216287 | 0.83 | CYP3A4 (0.51) | MAP4K4HTR2AHTR2CHTR2BPDE4A | |
| Methyl Alcohol SCHEMBL25211940 | 0.82 | CYP3A4 (0.50) | MAP4K4HTR2AHTR2CHTR2BPDE4A | |
| SCHEMBL3712352 | 0.81 | PDE4A (0.58) | MAP4K4MKNK1MKNK2PDE4APDE4B | |
| Hydrochloric Acid SCHEMBL25196157 | 0.81 | PARP1 (0.48) | MAP4K4NNMTSMN1; SMN2PARP10KMT2A | |
| Hydrochloric Acid SCHEMBL31095539 | 0.81 | PARP1 (0.48) | MAP4K4NNMTSMN1; SMN2PARP10KMT2A | |
| SCHEMBL1797083 | 0.81 | HTT (0.56) | MAP4K4ALDH1A1FGFR1MAPTTDP1 | |
| Hydrochloric Acid SCHEMBL25211938 | 0.79 | KDM4E (0.44) | MAP4K4HTR2AHTR2CHTR2BPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-08-31 | — | — | US | disclosed |
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-08-31 | — | — | US | disclosed |
| US-11661426-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661426-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271975-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | MAP4K4 131/4885NNMT 2801/4885SMN1; SMN2 989/4885 |
| US-11661426-B2 | Imidazole-containing inhibitors of ALK2 kinase | ALK, ACVR2B, ACVR2A | MAP4K4 131/4885NNMT 2801/4885SMN1; SMN2 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.